THOUSAND OAKS, Calif., May 9, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:20 a.m. PT on Wednesday, May 14 ...

Shares of Amgen Inc. AMGN slipped 1.37% to $272.05 Thursday, on what proved to be an all-around positive trading session for ...

Deep-pocketed investors have adopted a bearish approach towards Amgen AMGN, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

THOUSAND OAKS, Calif., April 28, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2025 financial results on Thursday, May 1, 2025, after the close of ...

THOUSAND OAKS, Calif., May 9, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:20 a.m. PT on Wednesday, May 14, 2025. Peter ...

Teprotumumab approved as first targeted treatment for thyroid eye disease The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Amgen’s Tepezza ...

Matthew C Busch, VP at Amgen AMGN, executed a substantial insider sell on May 7, according to an SEC filing. Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Amgen (AMGN – Research Report), with a price target of $329.00. The company’s shares closed last ...

After unveiling a new drug substance facility in North Carolina in December, Amgen is doubling down on expanding its U.S. production presence with plans for a major upgrade at its plant in central ...

Investors with a lot of money to spend have taken a bearish stance on Amgen (NASDAQ:AMGN). And retail traders should know. We noticed this today when the trades showed up on publicly available ...